Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 2, 2008, Pages 264-270

  Rossi, Emanuela ^a   Morabito, Alessandro ^a   De Maio, Ermelinda ^a   Di Rella, Francesca ^a   Esposito, Giuseppe ^a   Gravina, Adriano ^a   Labonia, Vincenzo ^a   Landi, Gabriella ^a   Nuzzo, Francesco ^a   Pacilio, Carmen ^a   Piccirillo, Maria Carmela ^a   D'Aiuto, Giuseppe ^a   D'Aiuto, Massimiliano ^a   Rinaldo, Massimo ^a   Botti, Gerardo ^a   Gallo, Ciro ^a   Perrone, Francesco ^a   De Matteis, Andrea ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CORTICOTROPIN; ESTRADIOL; FOLLITROPIN; HYDROCORTISONE; LETROZOLE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROGESTERONE; TAMOXIFEN; TESTOSTERONE; TRIPTORELIN; ZOLEDRONIC ACID;

ADULT; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; EARLY CANCER; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT REFUSAL; WILCOXON SIGNED RANKS TEST;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GONADAL HORMONES; HUMANS; MIDDLE AGED; NITRILES; PREMENOPAUSE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TRIPTORELIN;

EID: 38349098666     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5319     Document Type: Article

References (18)

1. Early Breast Cancer Trialist' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 365:1687-1717, 2005
2. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005
3. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
4. Thürlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
5. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271, 2005
6. Stein RC, Dowsett M, Hedley A, et al: The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679-683, 1990
7. Dowsett M, Doody D, Miall S, et al: Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25-34, 1999
8. Forward DP, Cheung KL, Jackson L, et al: Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590-594, 2004
9. Smith IE, Dowsett M, Yap YS, et al: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol 24:2444-2447, 2006
10. Carlson RW, Schurman CM, Rivera E, et al: Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer. J Clin Oncol 25:18S, 2007 (suppl; abstr 1030)
11. Celio L, Martinetti A, Ferrari L, et al: Premenopausal breast cancer patients treated with a gonadotropin releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 19(3b):2261-2268, 1999
12. Bajetta E, Zilembo N, Bichisao E, et al: Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann Oncol 11:1017-1022, 2000
13. Jannuzzo MG, Di Salle E, Spinelli R, et al: Estrogen suppression of 8-week treatment with exemestane combined with triptorelin versus triptorelin alone in healthy premenopausal women. J Clin Oncol 22:14S, 2004 (suppl; abstr 2041)
14. Tredway DR, Buraglio M, Hemsey G, et al: A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single-and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil Steril 82:1587-1593, 2004
15. Bisagni G, Cocconi G, Scaglione F, et al: Letrozole, a new oral non-steroidal aromatase inhibitor in treating postmenopausal patients with advanced breast cancer: A pilot study. Ann Oncol 7:99-102, 1996
16. Bajetta E, Zilembo N, Dowsett M, et al: Double-blind, randomized, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 35:208-213, 1999
17. Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30:103-111, 1994
18. Evans TR, di Salle E, Ornati G, et al: Phase I and endocrine study of exemestane (FCE24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 52:5933-5939, 1992